Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024.
- Revenue
- +3.95%
- EPS
- +34.8%
- Free cash flow
- −7.09%
- Total debt
- +15.6%
Quarter to September 2026, against a year earlier
Follow HSIC
Alert me
Henry Schein, Inc. (HSIC) EV/EBITDA
As of 5 November 2026, Henry Schein, Inc. (HSIC) trades at a EV/EBITDA of 11.4×. Over the past ten years it has ranged from 7.7× (April 2020) to 19.5× (December 2018); the current reading is higher than 33% of that period. That is below the Medical Distribution industry median of 17.3× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 11.7× | 3.62% |
| FY2024 | 11.3× | (14.43%) |
| FY2023 | 13.2× | 7.99% |
| FY2022 | 12.3× | 12.60% |
| FY2021 | 10.9× | (19.32%) |
| FY2020 | 13.5× | 16.23% |
| FY2019 | 11.6× | (15.51%) |
| FY2018 | 13.7× | 16.99% |
| FY2017 | 11.7× | 5.39% |
| FY2016 | 11.1× | (6.84%) |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 11.2× | (3.96%) |
| Jun 2026 | 11.7× | 6.86% |
| Mar 2026 | 10.9× | (6.86%) |
| Dec 2025 | 11.7× | 12.79% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| FOCL FocalTherics compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| ACH Accendra Health, Inc. compare | 8.1× |
| HSIC Henry Schein, Inc. | 11.4× |
| COR Cencora, Inc. compare | 17.3× |
| MCK McKesson Corporation compare | 17.7× |
| CAH Cardinal Health, Inc. compare | 17.9× |
| Medical Distribution industry median | 17.3× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on HSIC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement